UAE Biosimilars Market Research Report, 2030

The UAE Biosimilars market will grow as biosimilars are less expensive than their reference products, and patients can afford to use biosimilars as a therapy alternative. The United Arab Emirates (UAE) offers a sophisticated healthcare system with first-rate facilities and cutting-edge medical technology. The government offers free or inexpensive healthcare services to its inhabitants and residents, and the private sector meets the requirements of those who can afford to pay for private medical treatments. The country's healthcare system is a hybrid of the public and private sectors. The UAE government has made considerable investments in the healthcare industry over the years and is dedicated to offering top-notch services to its inhabitants and citizens. The government's spending on healthcare has been rising rapidly. This accounts for a considerable amount of the nation's GDP, demonstrating how important it is to the government that its citizens have access to quality healthcare services. In recent years, the UAE healthcare industry has seen a growth in the use of biosimilars as regulators and healthcare providers seek to expand access to reasonably priced biologic medicines. The Ministry of Health and Prevention (MOHAP) is in charge of the UAE's thorough regulatory framework for biosimilars. This framework, which is based on the rules established by the World Health Organisation (WHO) and the European Medicines Agency (EMA), demands that biosimilars show resemblance to the reference product in terms of quality, safety, and efficacy. According to the research report, “United Arab Emirates (UAE) Biosimilars Market Research Report, 2030” published by Actual Market Research, the United Arab Emirates (UAE) Biosimilars market is anticipated to grow at more than 19.45% CAGR from 2025 to 2030. The UAE market now offers a number of biosimilars, including versions of the drugs infliximab, etanercept, and rituximab. Rheumatoid arthritis, psoriasis, and cancer are just a few of the illnesses that are being treated with these products. Hence, the biosimilar market will grow across the nation during the forecast period. One of the main factors driving the market for biosimilars in the UAE is the high cost of branded biologics. Because they are typically less expensive than their reference products, patients can afford to use biosimilars as a therapy alternative. The UAE government is supporting the use of biosimilars by encouraging doctors to prescribe them and providing incentives to producers. As branded biologics' patents lapse, biosimilar producers will have the chance to enter the market and face off against more well-known names. The Ministry of Health and Prevention (MOHAP) is in charge of the UAE's regulatory framework for biosimilars. The European Medicines Agency (EMA) and the World Health Organisation (WHO) have both published recommendations that the MOHAP has adopted for the approval and registration of biosimilars in the nation. According to these regulations, biosimilars must undergo extensive testing before being authorized for use and show that they are comparable to the reference product in terms of quality, safety, and effectiveness.

What's Inside a Actual Market Research`s industry report?

Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globally

Download Sample

The healthcare system in Abu Dhabi is run by the Abu Dhabi Health Services Company (SEHA), which has devised a payment scheme for biosimilars based on clinical evidence, cost-effectiveness, and closeness to the reference product. Additionally, the SEHA has created a list of authorized biosimilars that are covered by the emirate's health insurance programs. Biosimilars are emerging as one of the most important sectors in the healthcare industry. With increasing healthcare costs, biosimilars are being looked upon as an affordable treatment option. Growing economies are observing comprehensive growth in the biosimilar market from demanding clinical needs of therapeutics. The rise in GDP and healthcare expenditures and the demand for cost-effective therapeutics solutions have resulted in this market's growth. The main health challenges within the Middle East and African region are beginning to reflect those in Western countries, with diabetes highly prevalent, with more than 1 in 10 adults suffering from it, and cancer-related mortality rates increasing. Economies in this region vary from country to country. While some countries in the region have been able to modify their healthcare expenditure to provide biosimilar therapies, others such as Egypt and Algeria are struggling. Government support and initiatives play a crucial role. Emerging pharmaceutical markets and lenient government regulations provide some of the major openings in this are market. The United Arab Emirates (UAE) biosimilars market has been witnessing steady growth, driven by the increasing demand for cost-effective and high-quality biologic medicines. Biosimilars are biological products that are highly similar to approved reference biologics, offering a more affordable alternative for patients and healthcare systems. In the UAE, as the government focuses on expanding access to healthcare and reducing healthcare expenditure, the adoption of biosimilars has gained traction. The market`s growth is influenced by the UAE robust regulatory framework for biosimilars, the prevalence of chronic diseases, and the impact of the Covid-19 pandemic on healthcare systems. The Covid-19 pandemic, which emerged in 2025, had a notable impact on the UAE biosimilars market. The pandemic put immense pressure on healthcare systems, leading to a heightened focus on cost-saving strategies and the need for affordable treatment options. Biosimilars, as cost-effective alternatives to reference biologics, became a key consideration for healthcare providers and policymakers to manage the increased demand for healthcare services during the pandemic. Key players leading this thriving market include pharmaceutical giants such as Sandoz International GmbH (a subsidiary of Novartis), Pfizer Inc., and Amgen Inc. These industry leaders are actively investing in research and development to develop high-quality biosimilars that meet stringent regulatory standards, providing safe and affordable alternatives to expensive biologics. Additionally, local players like Julphar Gulf Pharmaceutical Industries and Neopharma are making significant contributions to the market`s growth, reinforcing the country`s position as a hub for biosimilar production and distribution. Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years. By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding. Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer. There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. The immense potential of the biosimilars market has led to many recent, high-profile collaborations.

Make this report your own

We're excited to discuss your needs and our solutions. Let's schedule a call.

Ask an Expert

Nikita Jabrela

Business Development Manager

Considered in this report • Historic Year: 2019 • Base year: 2024 • Estimated year: 2025 • Forecast year: 2030 Aspects covered in this report • Biosimilars Market with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By Product • Monoclonal Antibodies • Insulin • Erythropoietin • Others (Includes recombinant glycosylated and non-glycosylated proteins)

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

By Application • Oncology • Chronic & Autoimmune Disorders • Blood Disorders • Growth Hormonal Deficiency • Infectious Disease • Others (Filgrastim/Pegfilgrastim, Teriparatide, Somatropin, Etanercept) By Manufacturer • In-house • Contract Research and Manufacturing Services The approach of the report: This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analyzing the government generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources. Intended audience This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to this industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.